| Bid | 2.69 |
| Market Cap | 2.42M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -147.36 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.95 |
| Volume | 143,768 |
| Avg. Volume (20D) | 5,872,642 |
| Open | 2.84 |
| Previous Close | 2.84 |
| Day's Range | 2.70 - 2.88 |
| 52-Week Range | 0.43 - 16.63 |
| Beta | undefined |
About PRFX
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the tre...
Analyst Forecast
According to 2 analyst ratings, the average rating for PRFX stock is "Buy." The 12-month stock price forecast is $48, which is an increase of 1632.85% from the latest price.
11 months ago · newsfilecorp.com
PainReform to Present at the Microcap Conference in Atlantic CityTel Aviv, Israel--(Newsfile Corp. - January 22, 2024) - PainReform Ltd. (NASDAQ: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation o...
